McKesson has received approval from The Centers for Medicare & Medicaid Services to participate in the Merit-based Incentive Payment System as a Qualified Clinical Data Registry.
It’s a divorce everyone has an opinion on.
McKesson approved as QCDR for 2021 MIPS Program Year
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
NIH and FDA envision transforming the way clinical trials are done across the biomedical research enterprise.
From the time of its inception, the Worldwide Innovative Network (WIN) Consortium in precision cancer medicine has had a bold mission to significantly improve survival of patients with cancer across the world through international collaboration.
As 2024 approaches, it’s anyone’s guess whether an already complex health care ecosystem gets to turn the corner on the mixed legacies of 2023—including record high prices on new blockbuster medications coupled with drug shortages on existing generics, persistent staff shortages and battered hospital margins, and a continued emphasis on value-based care programs by insurers.
To the editor, I was not booed off the stage. Rather, the response was incredibly enthusiastic. After my session people lined up for over 45 minutes to talk to me. Many thanked me for publicizing this issue, indicating that the problems with the Illumina platform have been apparent to many, but no one else was...
NCI’s Surveillance, Epidemiology, and End Results Program in the Division of Cancer Control and Population Sciences at NCI is marking 50 years of cancer surveillance.
